PT - JOURNAL ARTICLE AU - Cecília Artico Banho AU - Lívia Sacchetto AU - Guilherme Rodrigues Fernandes Campos AU - Cíntia Bittar AU - Fábio Sossai Possebon AU - Leila Sabrina Ullmann AU - Beatriz de Carvalho Marques AU - Gislaine Ceslestino Dutra da Silva AU - Marília Mazzi Moraes AU - Maisa Carla Pereira Parra AU - Andreia Francesli Negri AU - Ana Carolina Boldrin AU - Michela Dias Barcelos AU - Thayza M. I. L. dos Santos AU - Bruno H. G. A. Milhim AU - Leonardo Cecílio da Rocha AU - Fernanda Simões Dourado AU - Andresa Lopes dos Santos AU - Victoria Bernardi Ciconi AU - Caio Patuto AU - Alice Freitas Versiani AU - Rafael Alves da Silva AU - Edoardo Estevam de Oliveira Lobl AU - Victor Miranda Hernandes AU - Nathalia Zini AU - Carolina Colombelli Pacca AU - Cássia Fernanda Estofolete AU - Helena Lage Ferreira AU - Paula Rahal AU - João Pessoa Araújo, Jr. AU - Jamie A. Cohen AU - Cliff C. Kerr AU - Benjamin M. Althouse AU - Nikos Vasilakis AU - Mauricio Lacerda Nogueira TI - Effects of SARS-CoV-2 P.1 introduction and the impact of COVID-19 vaccination on the epidemiological landscape of São José Do Rio Preto, Brazil AID - 10.1101/2021.07.28.21261228 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.28.21261228 4099 - http://medrxiv.org/content/early/2021/07/31/2021.07.28.21261228.short 4100 - http://medrxiv.org/content/early/2021/07/31/2021.07.28.21261228.full AB - The emergence of the new Brazilian variant of concern, P.1 lineage (Gamma), raised concern about its impact on the epidemiological profile of COVID-19 cases due to its higher transmissibility rate and immune evasion ability. Using 272 whole-genome sequences combined with epidemiological data, we showed that P.1 introduction in São José do Rio Preto, São Paulo, Brazil, was followed by the displacement of eight circulating SARS-CoV-2 variants and a rapid increase in prevalence two months after its first detection. Our findings support that the P.1 variant is associated with an increase in mortality risk and severity of COVID-19 cases in younger aged groups, which corresponds to the unvaccinated population at the time. Moreover, our data highlight the beneficial effects of vaccination indicated by a pronounced reduction of severe cases and deaths in immunized individuals, reinforcing the need for rapid and massive vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge Rede Corona-Omica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP= 01.20.0029.000462/20, CNPq= 404096/2020-4, CNPq fellowship= 382032/2020-9 to C.A.B), FINEP (Grant #01180149-00), Multiuser Laboratory (LMU) at Sao Jose do Rio Preto School of Medicine (FAMERP), Brazil, for their support with the use of equipments (MiSeqTM, Illumina Inc, USA). Funding support is acknowledged from FAPESP-COVID Program (Grant #2020/04836-0 to MLN), JBS Support for COVID-19 Response Research, FAPESP fellowships (2020/07419-0 to GRFC), Fundacao Butantan (FAPESP Grant #2020/10127), Capes (Grant #0001), and partly by the Centers for Research in Emerging Infectious Diseases (CREID), The Coordinating Research on Emerging Arboviral Threats Encompassing the Neotropics (CREATE-NEO) grant 1U01AI151807 awarded to NV by the National Institutes of Health (NIH/USA). MLN, PR, JPAJ are CNPq Research Fellows. The funders had no role in the design of the study, collection, analyses, or interpretation of data, writing of the manuscript, or in the decision to publish the results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of Faculdade de Medicina de Sao Jose do Rio Preto Institutional Review Board (protocol number: CAE# 31588920.0.0000.5415)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability All SARS-CoV-2 genomes generated and analyzed in this study are available at EpiCoV database in GISAID (https://www.gisaid.org), and their respective access number are available at Supplementary Material. https://www.gisaid.org